Advertisement

The effect of 1-furan-2-yl-3-pyridine-2-yl-propenone on pharmacokinetic parameters of warfarin

  • Srinivasan Shanmugam
  • Eung Seok Lee
  • Tae Cheon Jeong
  • Chul Soon Yong
  • Han -Gon Choi
  • Jong -Soo Woo
  • Bong Kyu Yoo
Article Drug development

Abstract

1-Furan-2-yl-3-pyridine-2-yl-propenone (FPP-3) is an investigatory drug which has a dual inhibitory action on cyclooxygenase (COX) and 5-lipoxygenase (5-LOX). We examined its effect on the pharmacokinetics of warfarin. Three consecutive days of pretreatment with 17 mg/kg of FPP-3 had no significant effect on the pharmacokinetic parameters of warfarin when orally administered to rats. A higher dosage of FPP-3 however, did cause significant changes in the pharmacokinetic parameters of wafarin. The cytochrome P450 activity test demonstrated that the metabolism of R-warfarin was significantly inhibited by FPP-3 while there was little or no inhibition of the metabolism of S-warfarin, which is mainly responsible for its anticoagulant effect. Therefore, it appears that the alteration in the pharmacokinetic parameters of warfarin was due to the inhibitory effect of FPP-3 on the metabolism of R-warfarin. Although there was a significant increase in the plasma concentration, the area under the curve, half life of warfarin, and prothrombin time were not significantly changed. Based on these findings, the pharmacokinetic drug interaction between FPP-3 and warfarin mainly involves R-warfarin and, therefore, this interaction may not be of clinical significance in terms of warfarin-related toxicity.

Key words

1-Furan-2-yl-3-pyridine-2-yl-propenone Warfarin Pharmacokinetics Cytochrome P450 Prothrombin time 

References

  1. Belton, O., Byrne, D., Kearney, D., Leahy, A., and Fitzgerald, D., Cyclooxygenase-1 and-2-dependent prostacyclin formation in patients with atherosclerosis.Circulation, 102, 840–845 (2000).PubMedGoogle Scholar
  2. Blank, J., Tucker, A., Sweatlock, J., Gasiewicz, T., and Luster, M., Alpha-Naphthoflavone antagonism of 2,3,7,8-tetrachlo-rodibenzo-p-dioxin-induced murine lymphocyte ethoxyre-sorufin-O-deethylase activity and immunosuppression.Mol. Pharmacol., 32, 169–172 (1987).PubMedGoogle Scholar
  3. Burnier, M., The safety of rofecoxib. Expert Opin.Drug Saf., 4, 491–499 (2005).Google Scholar
  4. Clark, D., Layton, D., and Shakir S., Do some inhibitors of COX-2 increase the risk of thromboembolic events?: Linking pharmacology with pharmacoepidemiology.Drug Saf., 27, 427–456 (2004).PubMedCrossRefGoogle Scholar
  5. Crespi, C., Miller, V., and Penman, B., Microtiter plate assays for inhibition of human, drug-metabolizing cytochromes P450.Anal. Biochem., 248, 188–90 (1997).PubMedCrossRefGoogle Scholar
  6. Fiorucci, S., Meli, R., Bucci, M., and Cirino, G, Dual inhibitors of cyclooxygenase and 5-lipoxygenase. A new avenue in anti-inflammatory therapy?Biochem. Pharmacol., 62, 1433–1438 (2001).PubMedCrossRefGoogle Scholar
  7. Fosslien, E., Cardiovascular complications of non-steroidal anti-inflammatory drugs.Ann. Clin. Lab. Sci., 35, 347–385 (2005).PubMedGoogle Scholar
  8. Jahng, Y., Zhao, L, Moon, Y., Basnet, A., Kim, E., Chang, H., Ju, H., Jeong, T, and Lee, E., Simple aromatic compounds containing propenone moiety show considerable dual COX/ 5-LOX inhibitory activities. Bioorg.Med. Chem. Lett., 14, 2559–2562 (2004).CrossRefGoogle Scholar
  9. Joffe, H., Xu, R., Johnson, F., Longtine, J., Kucher, N., and Goldhaber, S., Warfarin dosing and cytochrome P450 2C9 polymorphisms.Thromb. Haemost., 91, 1123–1128 (2004).PubMedGoogle Scholar
  10. Kwan, D., Bartle, W., and Walker, S., The effects of acetaminophen on pharmacokinetics and pharmacodynamics of warfarin.J. Clin. Pharmacol., 39, 68–75 (1999).PubMedCrossRefGoogle Scholar
  11. Lee, E., Ju, H., Moon, T, Lee, E., Jahng, Y, Lee, S., Son, J., Baek, S., and Chang, H., Inhibition of nitric oxide and tumor necrosis factor-alpha (TNF-alpha) production by propenone compound through blockade of nuclear factor (NF)-kappa B activation in cultured murine macrophages.Biol. Pharm. Bull., 27, 617–620 (2004).PubMedCrossRefGoogle Scholar
  12. Lee, S., Jeon, T., Basnet, A., Jeong, H., Lee, E., and Jeong, T., Identification of 1-furan-2-yl-3-pyridin-2-yl-propenone, an antiinflammatory agent, and its metabolites in rat liver subcellular fractions.Arch. Pharm. Res., 29, 984–989 (2006).PubMedCrossRefGoogle Scholar
  13. Schmedtje, J., Ji, Y., Liu, W., DuBois, R., and Runge, M., Hypoxia induces cyclooxygenase-2 via the NF-kappaB p65 transcription factor in human vascular endothelial cells.J. Biol. Chem., 272, 601–608 (1997).PubMedCrossRefGoogle Scholar
  14. Shanmugam, S., Lee, E., Lee, S., Jeon, T., Yong, C., and Yoo, B., The Effect of 1-Furan-2-yl-3-pyridine-2-yl-propenone on Pharmacokinetic Parameters of Theophylline.Biol. Pharm. Bull., 29, 1282–1285 (2006).PubMedCrossRefGoogle Scholar
  15. Takeuchi, K., Tanaka, A., Hayashi, Y, and Yokota, A., COX inhibition and NSAID-induced gastric damage-roles in various pathogenic events.Curr. Top. Med. Chem., 5, 475–486 (2005).PubMedCrossRefGoogle Scholar
  16. Whelton, A., Renal and related cardiovascular effects of conventional and COX-2-specific NSAIDs and non-NSAID analgesics.Am. J. Ther., 7, 63–74 (2000).PubMedCrossRefGoogle Scholar
  17. Wolfe, F., Anderson, J., Burke, T., Arguelles, L, and Pettitt, D., Gastroprotective therapy and risk of gastrointestinal ulcers: risk reduction by COX-2 therapy.J. Rheumatol., 29, 467–473 (2002).PubMedGoogle Scholar
  18. Yacobi, A., Masson, E., Moros, D., Ganes, D., Lapointe, C., Abolfathi, Z., LeBel, M., Golander, Y, Doepner, D., Blumberg, T., Cohen, Y, and Levitt, B., Who needs individual bioequivalence studies for narrow therapeutic index drugs? A case for warfarin.J. Clin. Pharmacol., 40, 826–835 (2000).PubMedCrossRefGoogle Scholar

Copyright information

© The Pharmaceutical Society of Korea 2007

Authors and Affiliations

  • Srinivasan Shanmugam
    • 1
  • Eung Seok Lee
    • 1
  • Tae Cheon Jeong
    • 1
  • Chul Soon Yong
    • 1
  • Han -Gon Choi
    • 1
  • Jong -Soo Woo
    • 2
  • Bong Kyu Yoo
    • 1
  1. 1.College of PharmacyYeungnam UniversityKyungsanKorea
  2. 2.Central R&D CenterHanmi Pharm. Co. Ltd.GyunggiKorea

Personalised recommendations